ClinicalTrials.gg

Pulmonary Disease, Chronic Obstructive clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 5,526 studies for Pulmonary Disease, Chronic Obstructive across more than 10 countries. 858 are recruiting or about to start. 4,516 of them are mainly about Pulmonary Disease, Chronic Obstructive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Bronchitis, Chronic: 5,595 studies, 863 open.

ClinicalTrials.gov finds 6,477 studies for Pulmonary Disease, Chronic Obstructive. How that becomes 5,522 here

This page counts the studies the registry files under Pulmonary Disease, Chronic Obstructive, and those it files under no condition that list Pulmonary Disease, Chronic Obstructivethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 6,477Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −63Filed under a narrower condition, counted on its own pageBronchitis, Chronic 40 · Pulmonary Emphysema 22
  3. −45List Pulmonary Disease, Chronic Obstructive as a condition, but the registry did not file them under itMost often written as “COPD Exacerbation” (9), “Acute Exacerbation of Chronic Obstructive Pulmonary Disease” (6), and “Asthma-COPD Overlap Syndrome” (4). The registry filed them under other conditions only, most often Respiratory Insufficiency (7) and Pneumonia (5).
  4. −933Match it another way53 name it in the title, 1 in a keyword, and 879 by a synonym or other text the search reads.
  5. 5,436Counted here and found by its search93 of them list Pulmonary Disease, Chronic Obstructive in their own words; the registry filed them under no condition.
  6. +86
    Counted here, but its search does not find themThe first 20 of 86.
  7. 5,522The count on this page

Status

Completed
3,419
Status unknown
665
Recruiting
560
Terminated
298
Not yet recruiting
256
Withdrawn
141

Phase

Phase 2
567
Phase 3
555
Phase 4
442
Phase 1
357
Early Phase 1
34

Where

United States
1,279
United Kingdom
621
Germany
539
China
406
France
406
Canada
398

Who develops what

Add Pulmonary Disease, Chronic Obstructive to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 66 programs from 41 companies, 57 with this as their studies’ main aim; 18 with a live phase 3 study; 19 primary completions in the next 12 months. Compare Sino Biopharmaceutical, AstraZeneca and Joincare Pharmaceutical Group Industry here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
tiotropiumRecent, repeated
Evidence
  • NCT05986591 · xiromed llc · Phase 3 · comparator · “Spiriva Handihaler (Tiotropium Bromide) 18 mcg” · registered Aug 2023
  • NCT05165485 · Zymeworks · Phase 4 · comparator · “Tiotropium” · registered Dec 2021
  • NCT05161156 · phargentis sa · Phase 3 · comparator · “18 mcg of Spiriva (Reference Product)” · registered Dec 2021
  • NCT03673670 · Merck & Co., Inc · Phase 2 · background · “Tiotropium/olodaterol (Respimat)” · registered Sep 2018
  • NCT03478696 · GlaxoSmithKline · Phase 4 · background · “tiotropium” · registered Mar 2018
Boehringer Ingelheim71% of its industry studiesUS: off-patent, 1 generic marketed33 studies

13 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
TQC3721☆ Track2 live phase-3 studies: NCT07464587, NCT07147946Sino Biopharmaceutical Limited
HSK39004☆ Track3 live phase-3 studies: NCT07658339, NCT07583849, NCT07634367Haisco Pharmaceutical Group Co., Ltd.
JKN2401☆ Track1 live phase-3 study: NCT07330310Joincare Pharmaceutical Group Industry Co., Ltd.
BudesonideApproved: US · EU 2018☆ Track1 live phase-3 study: NCT06283966AstraZeneca
formoterolApproved: US☆ Track1 live phase-3 study: NCT06283966AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 66 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (19)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.rademikibart · Connect Biopharm LLC · Phase 2 named, not the main aimNCT07705737 Rademikibart IV for Acute Asthma and COPD Exacerbation — primary endpoint: Change from baseline in post-BD FEV1 · 40 enrolled
  • Dec 2026 est.TQC2731 · Sino Biopharmaceutical Limited · Phase 2 main aimNCT06707883 A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease — primary endpoint: Annual rate of acute COPD exacerbation · 258 enrolled
  • Feb 2027 est.TQC3721 · Sino Biopharmaceutical Limited · Phase 3 main aimNCT07464587 Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease — primary endpoint: Adverse event rate · 800 enrolled

16 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pulmonary Disease, Chronic Obstructive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 8 open · Antimuscarinics 6 open · Bronchodilators 4 open · PDE5 inhibitors 3 open · GLP-1 receptor agonists 2 open

Coming up

277studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger. 29 (5%) take children under 18. 1 (<1%) are for women only and 4 (1%) for men only; 88 (16%) take healthy volunteers.

Recruiting studies that take each age, of 560
AgeWomenMen
1027 (5%)28 (5%)
18265 (47%)266 (48%)
30303 (54%)304 (54%)
40510 (91%)510 (91%)
50540 (96%)543 (97%)
65540 (96%)541 (97%)
75509 (91%)510 (91%)
85393 (70%)394 (70%)

Across all 5,526 studies, recruiting or not: 17% stop at 75 or younger and 6% at 65; 8% take children; <1% are for women only and 3% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pulmonary Disease, Chronic Obstructive studies take

Of 176 phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 14 mo2–11 · 176 studies4 mo2–9 · 158 studies—
Phase 1/229 mo18–… · 21 studies——
Phase 217 mo10–31 · 166 studies14 mo7–20 · 119 studies39 mo20–63 · 47 studies
Phase 323 mo14–44 · 141 studies20 mo13–36 · 108 studies40 mo26–56 · 33 studies
Phase 419 mo12–40 · 157 studies15 mo9–22 · 71 studies29 mo14–50 · 86 studies
Interventional, no phase22 mo10–39 · 1,185 studies21 mo10–35 · 88 studies22 mo10–41 · 1,097 studies
Observational26 mo14–57 · 588 studies21 mo14–37 · 120 studies29 mo15–62 · 468 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting18

Show 13 more

Newly registered24

Show 19 more

Studies

Recruiting first, then most recently updated. Showing 50 of 5,526. Browse all 5,526 → or search them.